Evidence map›Paper›PMID 40023611›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Formoterol alters chemokine expression and ameliorates pain behaviors after moderate spinal cord injury in female mice.

Ingrid L Peterson, Natalie E Scholpa, Kiara J Bachtle, Jennifer B Frye, Sanna H Loppi, Austin D Thompson, Kristian Doyle, Tally Marie Largent-Milnes, Rick G Schnellmann

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ingrid L PetersonDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona.
Natalie E ScholpaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona; Southern Arizona VA Health Care System, Tucson, Arizona. Electronic address: nscholpa@arizona.edu.
Kiara J BachtleDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona.
Jennifer B FryeDepartment of Immunobiology, College of Medicine, University of Arizona, Tucson, Arizona.
Sanna H LoppiDepartment of Immunobiology, College of Medicine, University of Arizona, Tucson, Arizona.
Austin D ThompsonDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona.
Kristian DoyleSouthern Arizona VA Health Care System, Tucson, Arizona; Department of Immunobiology, College of Medicine, University of Arizona, Tucson, Arizona.
Tally Marie Largent-MilnesDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona.
Rick G SchnellmannDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona; Southern Arizona VA Health Care System, Tucson, Arizona; Department of Neuroscience, College of Medicine, University of Arizona, Tucson, Arizona; Southwest Environmental Health Science Center, University of Arizona, Tucson, Arizona; Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona. Electronic address: schnell@arizona.edu.

Funding

PHYSIOLOGYT32HL007249 · NHLBI · UNIVERSITY OF ARIZONA · PI Brett A Colson, JOHN P KONHILAS · 1985 to 2026
$12.5M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Targeting the Endocannabinoid System for Headache InterventionR01NS126752 · NINDS · UNIVERSITY OF ARIZONA · PI Tally Marie Milnes · 2023 to 2026
$2.4M
Primary Afferent Transmission in the Trigeminal Dorsal HornF32DE022499 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI MILNES, TALLY MARIE · 2011 to 2014
$127k
BLRD VA I01 BX004868BLRD VA IK2 BX005218NHLBI NIH HHS T32 HL007249NIDCR NIH HHS F32 DE022499NIEHS NIH HHS T32 ES007091NINDS NIH HHS R01 NS126752
6 · The paper itself

Abstract

Secondary spinal cord injury (SCI) is characterized by increased cytokines and chemokines at the site of injury that have been associated with the development of neuropathic pain. Nearly 80% of SCI patients report suffering from chronic pain, which is poorly managed with available analgesics. While treatment with the US Food and Drug Administration-approved β

Indexed as

Adrenergic beta-2 Receptor AgonistsBehavior, AnimalChemokinesFormoterol FumarateSpinal Cord InjuriesAnimalsFemaleMiceMice, Inbred C57BLNeuralgiaAdrenergic beta-2 Receptor AgonistsChemokinesFormoterol FumarateFormoterolMitochondrial biogenesisNeuroinflammationPainSpinal cord injury

Identifiers

PMID40023611
PMCPMC12571147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.